Eli Lilly’s Omvoh, Ebglyss, Kisunla, and Jaypirca added over $540M in revenues in H1 2025. The Zacks Consensus Estimate for LLY’s 2025 EPS rose to $22.97, and to $30.95 for 2026. Lilly saw market success with GLP-1 drugs Mounjaro and Zepbound, but also gained approvals for Omvoh, Ebglyss, Kisunla, and Jaypirca. These drugs contributed to revenue growth, with Omvoh, Ebglyss, Kisunla, and Jaypirca contributing $111.9M, $147.1M, $70.1M, and $215.3M, respectively. The company expects these new drugs to continue driving revenue growth in the second half of 2025.

Read more at Zacks Investment Research: Eli Lilly’s New Drugs Beyond Mounjaro and Zepbound Boost Sales – September 2, 2025